Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells.
We examined the effect of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand, on the intracellular free Ca(2+) concentrations in HL-60 cells that express the cannabinoid CB2 receptor. We found that 2-arachidonoylglycerol induces a rapid transient increase in intracellular free Ca(2+) concentrations in HL-60 cells. The response was affected by neither cyclooxygenase inhibitors nor lipoxygenase inhibitors, suggesting that arachidonic acid metabolites are not involved. Consistent with this notion, free arachidonic acid was devoid of any agonistic activity. Importantly, the Ca(2+) transient induced by 2-arachidonoylglycerol was blocked by pretreatment of the cells with SR144528, a CB2 receptor-specific antagonist, but not with SR141716A, a CB1 receptor-specific antagonist, indicating the involvement of the CB2 receptor but not the CB1 receptor in this cellular response. G(i) or G(o) is also assumed to be involved, because pertussis toxin treatment of the cells abolished the response. We further examined the structure-activity relationship. We found that 2-arachidonoylglycerol is the most potent compound among a number of naturally occurring cannabimimetic molecules. Interestingly, anandamide and N-palmitoylethanolamine, other putative endogenous ligands, were found to be a weak partial agonist and an inactive ligand, respectively. These results strongly suggest that the CB2 receptor is originally a 2-arachidonoylglycerol receptor, and 2-arachidonoylglycerol is the intrinsic natural ligand for the CB2 receptor that is abundant in the immune system.
Sugiura
T
T
Faculty of Pharmaceutical Sciences, Teikyo University, Sagamiko, Tsukui-gun, Kanagawa 199-0195, Japan.
Kondo
S
S
Kishimoto
S
S
Miyashita
T
T
Nakane
S
S
Kodaka
T
T
Suhara
Y
Y
Takayama
H
H
Waku
K
K
D000577:Amides; D001095:Arachidonic Acids / Q000378:metabolism*; D020013:Calcium Signaling; D001892:Camphanes / Q000494:pharmacology; D002186:Cannabinoids; D003511:Cyclohexanols / Q000494:pharmacology; D016861:Cyclooxygenase Inhibitors / Q000494:pharmacology; D004347:Drug Interactions; D063388:Endocannabinoids; D004983:Ethanolamines; D005989:Glycerides / Q000378:metabolism*; D018922:HL-60 Cells; D006801:Humans; D008024:Ligands; D016859:Lipoxygenase Inhibitors / Q000494:pharmacology; D018716:Molecular Mimicry; D010169:Palmitic Acids / Q000378:metabolism*; D037342:Pertussis Toxin; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles / Q000494:pharmacology; D012333:RNA, Messenger / Q000032:analysis; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists* / Q000037:antagonists & inhibitors / Q000145:classification / Q000235:genetics; D000077285:Rimonabant; D013329:Structure-Activity Relationship; D010566:Virulence Factors, Bordetella / Q000494:pharmacology
D000577:Amides; D001095:Arachidonic Acids; D001892:Camphanes; D002186:Cannabinoids; D003511:Cyclohexanols; D016861:Cyclooxygenase Inhibitors; D063388:Endocannabinoids; D004983:Ethanolamines; D005989:Glycerides; D008024:Ligands; D016859:Lipoxygenase Inhibitors; D010169:Palmitic Acids; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D012333:RNA, Messenger; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C110630:SR 144528; D010566:Virulence Factors, Bordetella; C005958:palmidrol; C054649:3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol; C094503:glyceryl 2-arachidonate; D037342:Pertussis Toxin; D000077285:Rimonabant; C078814:anandamide